



MENTAL HEALTH

Living well for longer

2017 update

Pharmacy Guidance on Smoking and Mental Disorder

KEY LEARNING POINTS

- » Smoking is the single largest cause of preventable death in the UK and a major determinant of health inequality for those with a mental disorder.
- » With appropriate support, those with a mental disorder are able to stop smoking.
- » Doses of some psychiatric medication require significant reduction following smoking cessation.
- » A range of pharmacological interventions (such as combination nicotine replacement therapy or varenicline) and non-pharmacological interventions are effective in supporting smoking cessation for people with a mental disorder.
- » Pharmacists have a key role in improving access to smoking cessation and reduction interventions for smokers with a mental disorder as well as facilitating appropriate changes of medication doses.

Smoking – the biggest killer

Smoking is associated with an increased risk of several chronic diseases¹ and is the single largest cause of preventable death with smokers dying on average 10 years earlier than non-smokers². In 2014, there were 78,000 deaths attributable to smoking in England³.

Smoking and mental disorder

People with different mental disorders have a 10-20 year lower life expectancy with smoking recognised as the single largest preventable cause. Since 42% of adult tobacco consumption in England is by those with a mental disorder⁴, this group experiences a significant proportion of overall tobacco related harm. Furthermore, the annual health service cost of smoking by those with a mental disorder in the UK was £719m in 2009/10⁵.

Smoking cessation and reduction in those with a mental disorder

Smoking cessation results in improved physical and mental health¹. Furthermore, evidence suggests that the impact of smoking cessation on anxiety and depressive symptoms is at least as large as antidepressants⁶. Smoking cessation is the single largest way to reduce the 10-20 year premature mortality experienced by those with a mental disorder.

Pharmacotherapy and non-pharmacological support are effective in supporting smoking cessation in those with a mental disorder¹. Furthermore, interventions can also support people who are not ready to stop smoking completely by helping them to reduce the amount they smoke. Over time this can help to double smoking cessation rates⁷.

Despite being as motivated to stop as the general population, those with a mental disorder are less likely to receive smoking cessation interventions. Taking action to support those with a mental disorder

to quit smoking should be even more imperative, given the rates of comorbid physical health problems and reduced life expectancy within this population.

Medication dose reduction following smoking cessation

Smoking increases the metabolism of different medications, including some antidepressants (tricyclics and mirtazapine), antipsychotics (clozapine, olanzapine and haloperidol)^{8,9}, some benzodiazepines and opiates¹⁰. This can result in significantly lower plasma levels¹¹ and therefore, larger doses are required for a similar therapeutic effect. Stopping smoking can reduce metabolism of some medication resulting in higher, sometimes toxic plasma levels over a few days^{11,12}. Therefore, close monitoring is required and doses of the medications above need to be reduced within days of cessation and by up to 50% within a month of cessation. It is recommended that¹²:

- Plasma levels of clozapine (and olanzapine if assays are available) should be measured before smoking cessation to enable more accurate and timely monitoring

and adjustment of medications. Doses of clozapine and olanzapine should be reduced by 25% during the first week of cessation and then further plasma levels taken on a weekly basis until levels have stabilised

- Doses of fluphenazine and some benzodiazepines should be reduced by up to 25% in the first week of cessation
- Tricyclic antidepressants may need to be reduced by 10-25% in the first week
- Further dose reductions may be required with continued cessation

Dose reduction of psychotropic medication following smoking cessation in those with a mental disorder in the UK would result in associated annual NHS savings of £40m⁵.

Medication dose reduction following smoking reduction

Smoking reduction decreases the associated harm and increases the chances of stopping smoking among smokers in the general population¹³. Smoking reduction can also decrease the metabolism of some medication. However, there is an important research gap regarding required dose changes for people who reduce their smoking but do not stop completely. In such cases, monitoring which includes regular blood tests for drug levels should inform such changes.

Role of pharmacists

Pharmacists are highly accessible to different groups of the local population and are in an ideal position to:

- Explain how smoking cessation can improve mental health as well as physical health
- Encourage people to stop smoking through promoting healthy lifestyles which is part of the pharmacy contractual framework
- Check drug interactions between medicines prescribed and/or taken as supplements
- Highlight to patients and prescribers the need for planned reduction of doses of some medications upon smoking cessation (as outlined above)
- Encourage the use of combined NRT to all including those who continue to smoke which supports smoking reduction as a first step to cessation
- Supply smoking cessation pharmacotherapy through Patient Group Directions (PGDs) or as part of a local Enhanced Service
- Coordinate pharmacy support with community and inpatient mental health services, primary care providers and local Stop Smoking Services to offer ongoing smoking cessation support as part of a more integrated service

Pharmacy staff who are trained to provide advice on stopping smoking are likely to improve the support pharmacies can offer to people who wish to stop.

Smoking cessation and reduction pharmacotherapy

Several different types of smoking cessation pharmacotherapy exist. When comparing different types of pharmacotherapy for the general population, be aware that^{15, 16}:

- Different types of NRT are similarly effective for smoking cessation with nasal spray being slightly more effective followed by tablets/lozenges, inhalers, patches and gum which is slightly less effective
- NRT and bupropion are equally effective
- Varenicline is more effective than bupropion or single forms of NRT
- Varenicline is as effective as combined NRT
- Addition of bupropion or nortriptyline does not increase effectiveness of NRT

A combination of different forms of NRT and NRT/bupropion reduces smoking consumption in people with a mental disorder^{5, 13, 14}.

Nicotine replacement therapy (NRT)

NRT is effective (OR 1.84, 1.71-1.99)¹⁵. Several different forms of NRT can be prescribed^{16, 17}. The choice of which form to use should reflect patient needs, tolerability and cost considerations. Patches are likely to be easier to use than gum, nasal spray or inhaler although patches cannot be used for relief of acute cravings¹⁶. The use of local Enhanced Services can also be considered in order to improve access:

- Patches: 16-hour and 24-hour patches are available with no difference in efficacy. Both types come in several strengths to allow gradual weaning. A high dose patch should be used for those who normally smoke more than 20 cigarettes per day
- Gum: 2mg, 4mg or 6mg, up to 15 pieces daily can be chewed at regular intervals
- Sublingual tablets: one (2mg) tablet per hour for those smoking 20 cigarettes daily and two tablets per hour for those smoking 40 cigarettes daily
- Oral film: 2.5mg dissolved in the mouth up to 15 times a day
- Nasal spray: (500mcg) maximum dose 2 sprays per nostril per hour for up to 16 hours per day
- Oral spray: 1 or 2 sprays of 1mg, up to 4 sprays per hour to a maximum of 64 sprays a day
- Inhalator: mouthpiece. The initial dose should be up to twelve 10mg cartridges, or six 15mg cartridges per day
- Lozenges: 1mg, 1.5mg, 2mg and 4 mg up to maximum 15 per day

Combining a nicotine patch with a rapid-delivery form of NRT is more effective than a single type of nicotine replacement^{15, 16} particularly for more dependent smokers including those with a mental disorder who may need longer than the recommended 8-12 weeks treatment^{5, 14}. Only cigarette smoking induces hepatic enzymes to alter drug plasma levels in the ways described above; NRT has no effect on enzyme activity and therefore drug doses are not affected although require accompanying dose reductions of medications outlined above upon smoking cessation.

Side effects^{15, 17}

- Patches: Skin sensitivity and irritation
- Gum: Hiccoughs, gastrointestinal problems, jaw pain and orodental problems

- Sublingual tablets: Hiccoughs, burning, sore throat, coughing and dry lips
- Nasal/oral spray and inhalers: Local irritation
- Serious adverse effects are absent from trial reports although there have been reports of possible increased risk of chest pain and heart problems

E-cigarettes

Although there is a lack of evidence about long term safety and more research is needed, e-cigarettes are widely considered to be much less harmful than cigarette smoking¹⁸ and used by 4% of adults in England³. The main reasons for e-cigarette use are to aid stop smoking (53%) and being less harmful than cigarettes³. As for other forms of NRT, e-cigarettes do not induce enzymes and so require accompanying dose reductions of medications outlined above if completely replacing tobacco smoking.

Bupropion

Bupropion is an atypical antidepressant which acts as an adrenaline and dopamine reuptake inhibitor as well as nicotinic antagonist thereby reducing nicotine cravings and withdrawal symptoms. Bupropion is effective in the general population for smoking cessation (OR 1.82, 1.60-2.06) with a combination of NRT and bupropion more effective than bupropion alone¹⁵. For people with schizophrenia, bupropion almost triples cessation rates at six months¹⁹.

Dosing: start 1-2 weeks before planned quit date at 150mg daily for 6 days, then 150mg twice daily for maximum 7-9 weeks.

Side effects

- Dry mouth (10%), constipation, nausea, insomnia (30-40%) and allergic reactions¹⁵
- Serious adverse effects (SAEs)
 - » Seizures: Seizure rate (0.1%) was low although a report found it was much higher in accidental and intentional overdoses (6%). Rates were lower for sustained-release formulations
 - » Spontaneous abortion
 - » MHRA described reports of bupropion being associated with the development of depression, suicidal thoughts and behaviours, hallucinations, delusions, disordered thoughts and extreme mood swings. These effects were more likely in people who have had mental health problems before²⁰
 - » In 2009, the FDA required bupropion to carry the agency's strongest safety warning due to side effects including changes in behaviour, hostility, agitation, depressed mood, suicidal thoughts and behaviour, and attempted suicide including in those with no previous history of psychiatric illness²¹
 - » However, a meta-analysis of six trials found no difference in neuropsychiatric SAEs between bupropion and placebo¹⁵. A further large prospective study found no increased risk of depression or suicidal behaviour²²
 - » A meta-analysis of bupropion for people with schizophrenia found no reported serious adverse events¹⁹. A more recent trial involving more than 4,000 people with a history of psychiatric disorder

found that bupropion did not significantly increase the risk of neuropsychiatric adverse events²³

Contraindications

Bupropion is contraindicated for people with bipolar disorder and epilepsy. It should not be prescribed to people who have recently stopped taking sedatives or medicines to treat anxiety, eating disorder or who are heavy drinkers²⁰.

Interactions

Bupropion should not be prescribed with other drugs which increase risk of seizure such as tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs) and some antipsychotic medication including clozapine, chlorpromazine and depot injections¹². Bupropion can increase blood levels of citalopram so should not be taken concurrently and should be avoided for two weeks after stopping¹⁷. However, the two drugs have been used safely as co-therapy²⁴.

Varenicline

Varenicline (OR 2.88, 2.40-3.47) is a nicotine receptor partial agonist and as effective as combination NRT although more effective than either single form NRT or bupropion¹⁵.

Dosing: Usually started 1-2 weeks before target stop date at 500mcg daily for 3 days, then 500mcg twice daily for 4 days and then increased to 1mg twice daily for a further 11 weeks.

Side effects

- Main side effect is nausea while other common side effects include insomnia, abnormal dreams and headaches¹⁵
- Serious adverse effects (SAEs)

- » A meta-analysis found no increased rate of any SAE or neuropsychiatric SAE in people taking varenicline compared to placebo¹⁵. A further large prospective study found no increased risk of depression or suicidal behaviour²². A more recent trial involving more than 4,000 people with a history of psychiatric disorder found that varenicline did not significantly increase the risk of neuropsychiatric adverse events²³
- » In 2009, the FDA required varenicline to carry the agency's strongest safety warning due to side effects including changes in behaviour, hostility, agitation, depressed mood, suicidal thoughts and behaviour, and attempted suicide including in those with no previous history of psychiatric illness²¹. However, the EMA has recently removed the black box warning²⁵ following further evaluation outlined above
- » Changes in behaviour or thinking, anxiety, psychosis, mood swings, aggressive behaviour, depression, suicidal ideation and behaviour and suicide attempts have been reported in patients taking varenicline in post-marketing surveillance²⁵

Need for close monitoring while taking bupropion and varenicline

- If patients taking varenicline or bupropion develop suicidal thoughts, agitation, depressed mood, or display any changes in behaviour which are of concern for the doctor, pharmacist, patient, family, or carer, they should stop bupropion or varenicline and contact their doctor immediately^{20, 25}

- Care should be taken with patients with a history of psychiatric illness and patients should be advised accordingly²⁵
- Close, regular monitoring by health professionals including psychiatrists, GPs and community health staff should occur through a clearly negotiated plan of support and contact especially in the first 2-3 weeks with clear strategies for responding in the event of changes
- If varenicline or bupropion is stopped due to neuropsychiatric symptoms, patients should be monitored closely until the symptoms resolve
- Family members and carers should also be alerted to the potential for such changes and be an active part of any negotiated support plan, with the person's consent

Nortriptyline and cytisine

Evidence also highlights the effectiveness of nortriptyline (OR 2.03, 1.48-2.78) and cytisine (OR 3.98, 2.01-7.87) without significant adverse effects¹⁵. However, these treatments are unlicensed in the UK.

Level of smoking cessation pharmacotherapy provision and associated expenditure

Over the last ten years in England, the number of smoking cessation prescription items dispensed has reduced from 2 million to 1.3 million³. This has been primarily due to a reduction of NRT items dispensed from 2.1 million to 0.8 million. There has been a similar 42% reduction in net ingredient cost from £65.9 million in 2010/11 to £38.1 million in 2014/15 (3). In contrast, there are 2.2 million current users of e-cigarettes. ■

Useful Resources

Royal College of Psychiatrists (2016) Improving the physical health of adults with severe mental illness: essential actions (OP100). Working Group for Improving the Physical Health of People with SMI
<http://www.rcpsych.ac.uk/files/pdfversion/OP100.pdf>

HSCIC (2015) Statistics on NHS Stop Smoking Services: England 2015
<http://www.hscic.gov.uk/catalogue/PUB17526/stat-smok-eng-2015-rep.pdf>

Campion J, Shiers D, Britton J, Gilbody S, Bradshaw T (2014) Primary care guidance on smoking and mental disorders – 2014 update. Royal College of General Practitioners & Royal College of Psychiatrists
<http://www.rcpsych.ac.uk/pdf/PrimaryCareGuidanceonSmokingandMentalDisorders2014update.pdf>

Royal Pharmaceutical Society (2014) Policy statement on e-cigarettes
<http://www.rpharms.com/policy-pdfs/e-cigarettes---ps---201402.pdf>

National Centre for Smoking Cessation and Training (2014) Local Stop Smoking Services: Service and delivery guidance 2014.
http://www.ncsct.co.uk/publication_service_and_delivery_guidance_2014.php

Royal College of Physicians/Royal College of Psychiatrists (2013) Smoking and mental health. A joint report.
https://www.rcplondon.ac.uk/sites/default/files/smoking_and_mental_health_-_full_report_web.pdf

NICE (2013) Smoking: acute, maternity and mental health services.
<https://www.nice.org.uk/guidance/PH48>

NICE (2013) Tobacco harm reduction.
<http://www.nice.org.uk/ph45>

NHS Smokefree Support Services.
<http://www.nhs.uk/smokefree/help-and-advice/support#lzL011SJDPOypz8q.97> and Helpline on 0300 123 1044

Free local NHS Stop Smoking Service.
<http://www.nhs.uk/smokefree/help-and-advice/local-support-services-helplines>

Help at Hand leaflet produced by the Royal College of Psychiatrists provides information to smokers and staff and can be downloaded at
<http://www.rcpsych.ac.uk/mentalhealthinfo/problems/smokingandmentalhealth.aspx>

Authors

Dr Jonathan Campion is a Consultant Psychiatrist and Director of Public Mental Health at South London and Maudsley NHS Foundation Trust.
Email: Jonathan.Campion@slam.nhs.uk

Mr Jed Hewitt is Chief Pharmacist at Sussex Partnership NHS Foundation Trust.

Dr David Shiers is Honorary Reader in Early Psychosis for the University of Manchester

Professor David Taylor is Chief Pharmacist at South London and Maudsley NHS Foundation Trust.

To cite: Campion J, Hewitt J, Shiers D, Taylor D (2017) *Pharmacy guidance on smoking and mental disorder – 2017 update*. Royal College of Psychiatrists, National Pharmacy Association and Royal Pharmaceutical Society.

We also wish to acknowledge the following people for their helpful comments and advice:

- Professor Ann McNeill (National Addiction Centre, King's College London)
- Professor Sharon Lawn (Flinders University, Australia)
- Dr Debbie Robson (National Addiction Centre, King's College London)
- Siobhan Gea (Principal Pharmacist, Bethlam Royal Hospital, South London and Maudsley NHS Foundation Trust)
- Leyla Hannbeck (Chief Pharmacist, National Pharmacy Association), Sana Din and Shivani Patel (Advice and Support Pharmacist, National Pharmacy Association)
- Ruth Wakeman (Assistant Director for Professional Development and Support, Royal Pharmaceutical Society)

This resource was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Design: Astrid Johnson Graphic Design – affordable design and print for the public sector, not-for-profit organisations, social enterprises and small businesses, email astridjohnson@icloud.com.

Endorsements

Royal College of Psychiatrists (RCPsych)

Royal College of General Practitioners (RCGP)

National Pharmacy Association

Royal Pharmaceutical Society

Iris



Royal College of
General Practitioners



References

- 1 Campion J, Shiers D, Britton J, Gilbody S, Bradshaw T (2014) Primary care guidance on smoking and mental disorders – 2014 update. Royal College of General Practitioners & Royal College of Psychiatrists
- 2 Doll R, Peto R, Boreham J, Sutherland I (2004) Mortality in relation to smoking: 50 years' observation on male British doctors. *British Medical Journal*. 328: 745
- 3 HSCIC (2016) Statistics on NHS Stop Smoking Services: England 2016 <http://content.digital.nhs.uk/catalogue/PUB20781/stat-smok-eng-2016-rep.pdf>
- 4 McManus S, Meltzer H, Campion J (2010) Cigarette smoking and mental health in England. Data from the Adult Psychiatric Morbidity Survey. National Centre for Social Research. <http://www.natcen.ac.uk/media/21994/smoking-mental-health.pdf>
- 5 RCP/RCPsych (2013) Smoking and mental health. A joint report. https://www.rcplondon.ac.uk/sites/default/files/smoking_and_mental_health_-_full_report_web.pdf
- 6 Taylor G, McNeill A, Girling A et al (2014) Change in mental health after smoking cessation: systematic review and meta-analysis. *BMJ* 348: g1151
- 7 Lindson-Hawley N, Hartmann-Boyce J, Fanshawe T et al (2016) Interventions to reduce harm from continued tobacco use. *Cochrane Database of Systematic Reviews*, Issue 10. Art. No.: CD005231. DOI: 10.1002/14651858.CD005231.pub3.
- 8 Bazire, S (2009) Psychotropic Drug Directory 2003/2004. Fivepin Publishing
- 9 Tsuda Y, Saruwatari J, Yasui-Furukori N (2014) Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. *BMJ Open* 2014;4:e004216.doi:10.1136/bmjopen-2013-004216
- 10 Schall US, Pries E, Katta T et al (1996) Pharmacokinetic and pharmacodynamic interactions in an outpatient maintenance therapy of intravenous heroin users with levomethadone. *Addiction Biology*, 1, 105–113
- 11 Campion J, Checinski K, Nurse J (2008) Review of smoking cessation treatments for people with mental illness. *Advances in Psychiatric Treatment* 14: 208–216
- 12 Taylor D, Paton C, Kapur S (2015) *The Maudsley Prescribing Guidelines*, 12th Edition. Wiley-Blackwell, London, UK.
- 13 NICE (2013) Tobacco harm reduction <http://www.nice.org.uk/ph45>
- 14 NICE (2013) Smoking: acute, maternity and mental health services. <https://www.nice.org.uk/guidance/ph48>
- 15 Cahill K, Stevens S, Perera R, et al (2013) Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev* 5: CD009329
- 16 Stead L, Perera R, Bullen C et al (2012) Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews* Issue 11, CD000146. DOI: 10.1002/14651858.CD000146.pub4. Wiley InterScience
- 17 British Medical Association & Royal Pharmaceutical Society of Great Britain (2015) *British National Formulary*. BMJ Books and Pharmaceutical Press
- 18 McNeill A, Brose LS, Calder R et al (2015) E-cigarettes: an evidence update. A report commissioned by Public Health England https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/457102/E-cigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf
- 19 Tsoi D, Porwal M, Webster A (2010) Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. *Br J Psychiatry* 196: 346–353
- 20 MHRA (2016) Product info for bupropion <http://www.mhra.gov.uk/spc-pil/?prodName=ZYBAN%20150%20MG%20PROLONGED%20RELEASE%20FILM-%20COATED%20TABLETS&subName=&pageID=ThirdLevel&searchTerm=bupropion%20#retainDisplay>
- 21 Food and Drug Administration (2009) Information for Healthcare Professionals: Varenicline and Bupropion <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm169986.htm>
- 22 Thomas K, Martin R, Davies N et al (2013) Smoking cessation treatment and risk of depression, suicide and self-harm in the Clinical Practice Research Datalink: prospective cohort study. *BMJ* 347:f5704
- 23 Anthenelli R, Benowitz N, West R et al (2016) Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomized, placebo-controlled clinical trial. *Lancet* 387(10037): 2507–20
- 24 Trivedi MH, Fava M, Wisniewski SR et al (2006) A comparison of citalopram augmentation with bupropion-SR and buspirone following SSRI failure for depressed outpatients: A STAR*D report. *N Engl J Med* 354:1243–1252
- 25 European Medicines Agency (2016) Champix summary of product characteristics http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000699/human_med_000696.jsp